Cognoptix announced that its Sapphire II eye test identified Alzheimer’s patients via a beta amyloid signature in their eyes in a 10-subject proof-of-concept clinical trial, according to a company press release.
See Also New approach to services improves access to eye care in ... Vision Council educates Congress on low vision in veterans ... New WCO president: Access to care a primary goal ... The Sapphire II is an in-office, drug/device diagnostic system designed as an aid in the early detection of Alzheimer’s disease pathology. A ligand or contrast agent and software-controlled optical instrument allows for noninvasive detection and assessment of Alzheimer’s by measuring its hallmark, beta amyloid, in the supranuclear region of the lens of the eye, the release said.
